Cargando…

Evaluating targeted COVID-19 vaccination strategies with agent-based modeling

We evaluate approaches to vaccine distribution using an agent-based model of human activity and COVID-19 transmission calibrated to detailed trends in cases, hospitalizations, deaths, seroprevalence, and vaccine breakthrough infections in Florida, USA. We compare the incremental effectiveness for fo...

Descripción completa

Detalles Bibliográficos
Autores principales: Hladish, Thomas J., Pillai, Alexander N., Pearson, Carl A. B., Toh, Kok Ben, Tamayo, Andrea, Stoltzfus, Arlin, Longini, Ira M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cold Spring Harbor Laboratory 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10029084/
https://www.ncbi.nlm.nih.gov/pubmed/36945423
http://dx.doi.org/10.1101/2023.03.09.23285319
_version_ 1784910074057064448
author Hladish, Thomas J.
Pillai, Alexander N.
Pearson, Carl A. B.
Toh, Kok Ben
Tamayo, Andrea
Stoltzfus, Arlin
Longini, Ira M.
author_facet Hladish, Thomas J.
Pillai, Alexander N.
Pearson, Carl A. B.
Toh, Kok Ben
Tamayo, Andrea
Stoltzfus, Arlin
Longini, Ira M.
author_sort Hladish, Thomas J.
collection PubMed
description We evaluate approaches to vaccine distribution using an agent-based model of human activity and COVID-19 transmission calibrated to detailed trends in cases, hospitalizations, deaths, seroprevalence, and vaccine breakthrough infections in Florida, USA. We compare the incremental effectiveness for four different distribution strategies at four different levels of vaccine availability, reflecting different income settings’ historical COVID-19 vaccine distribution. Our analysis indicates that the best strategy to reduce severe outcomes is to actively target high disease-risk individuals. This was true in every scenario, although the advantage was greatest for the middle-income-country availability assumptions, and relatively modest compared to a simple mass vaccination approach for rapid, high levels of vaccine availability. Ring vaccination, while generally the most effective strategy for reducing infections, ultimately proved least effective at preventing deaths. We also consider using age group as a practical, surrogate measure for actual disease-risk targeting; this approach still outperforms both simple mass distribution and ring vaccination. We also find that the magnitude of strategy effectiveness depends on when assessment occurs (e.g., after delta vs. after omicron variants). However, these differences in absolute benefit for the strategies do not change the ranking of their performance at preventing severe outcomes across vaccine availability assumptions.
format Online
Article
Text
id pubmed-10029084
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Cold Spring Harbor Laboratory
record_format MEDLINE/PubMed
spelling pubmed-100290842023-03-22 Evaluating targeted COVID-19 vaccination strategies with agent-based modeling Hladish, Thomas J. Pillai, Alexander N. Pearson, Carl A. B. Toh, Kok Ben Tamayo, Andrea Stoltzfus, Arlin Longini, Ira M. medRxiv Article We evaluate approaches to vaccine distribution using an agent-based model of human activity and COVID-19 transmission calibrated to detailed trends in cases, hospitalizations, deaths, seroprevalence, and vaccine breakthrough infections in Florida, USA. We compare the incremental effectiveness for four different distribution strategies at four different levels of vaccine availability, reflecting different income settings’ historical COVID-19 vaccine distribution. Our analysis indicates that the best strategy to reduce severe outcomes is to actively target high disease-risk individuals. This was true in every scenario, although the advantage was greatest for the middle-income-country availability assumptions, and relatively modest compared to a simple mass vaccination approach for rapid, high levels of vaccine availability. Ring vaccination, while generally the most effective strategy for reducing infections, ultimately proved least effective at preventing deaths. We also consider using age group as a practical, surrogate measure for actual disease-risk targeting; this approach still outperforms both simple mass distribution and ring vaccination. We also find that the magnitude of strategy effectiveness depends on when assessment occurs (e.g., after delta vs. after omicron variants). However, these differences in absolute benefit for the strategies do not change the ranking of their performance at preventing severe outcomes across vaccine availability assumptions. Cold Spring Harbor Laboratory 2023-03-10 /pmc/articles/PMC10029084/ /pubmed/36945423 http://dx.doi.org/10.1101/2023.03.09.23285319 Text en https://creativecommons.org/licenses/by-nc-nd/4.0/This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (https://creativecommons.org/licenses/by-nc-nd/4.0/) , which allows reusers to copy and distribute the material in any medium or format in unadapted form only, for noncommercial purposes only, and only so long as attribution is given to the creator.
spellingShingle Article
Hladish, Thomas J.
Pillai, Alexander N.
Pearson, Carl A. B.
Toh, Kok Ben
Tamayo, Andrea
Stoltzfus, Arlin
Longini, Ira M.
Evaluating targeted COVID-19 vaccination strategies with agent-based modeling
title Evaluating targeted COVID-19 vaccination strategies with agent-based modeling
title_full Evaluating targeted COVID-19 vaccination strategies with agent-based modeling
title_fullStr Evaluating targeted COVID-19 vaccination strategies with agent-based modeling
title_full_unstemmed Evaluating targeted COVID-19 vaccination strategies with agent-based modeling
title_short Evaluating targeted COVID-19 vaccination strategies with agent-based modeling
title_sort evaluating targeted covid-19 vaccination strategies with agent-based modeling
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10029084/
https://www.ncbi.nlm.nih.gov/pubmed/36945423
http://dx.doi.org/10.1101/2023.03.09.23285319
work_keys_str_mv AT hladishthomasj evaluatingtargetedcovid19vaccinationstrategieswithagentbasedmodeling
AT pillaialexandern evaluatingtargetedcovid19vaccinationstrategieswithagentbasedmodeling
AT pearsoncarlab evaluatingtargetedcovid19vaccinationstrategieswithagentbasedmodeling
AT tohkokben evaluatingtargetedcovid19vaccinationstrategieswithagentbasedmodeling
AT tamayoandrea evaluatingtargetedcovid19vaccinationstrategieswithagentbasedmodeling
AT stoltzfusarlin evaluatingtargetedcovid19vaccinationstrategieswithagentbasedmodeling
AT longiniiram evaluatingtargetedcovid19vaccinationstrategieswithagentbasedmodeling